Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Corporate Update (August 2018)
20 slides from Precigen's corporate update, Aug 9, 2018
Slide 1: Intrexon Corporation Business Update August 2018
Intrexon Corporation Business Update August 9 2018 Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are bas
Slide 3: About Us
About Us New approaches to gene and cell therapy that target: Underlying causes of disease Multiple genes with a single therapy Reduction of patient cost and wait time for cellular therapies Precision bioengineering to address: Risks to global food production resulting from growing resistance to pes
Slide 4: Advancing Syn-Bio Across Platforms
intrexon — Advancing Syn-Bio Across Platforms CAR mbIL-15 8 CAR mbIL-15 7 mbIL-15 CAR 2018: The Year of Energy & Healthcare 2019: The Year of Plants & Animals
Slide 5: Intrexon's Methane Bioconversion Platform (MBP)
intrexon’s Methane Bioconversion Platform (MBP) Engineering microbes for industrial applications © 2018 Intrexon Corp. All rights reserved.
Slide 6: Proprietary methane bioconversion platform
intrexon’s proprietary methane bioconversion platform is a ground-breaking approach in the Gas-to-Liquids (GTL) industry. Over past several years intrexon has built a proprietary genetic toolbox for MBP to unlock its potential in methane bioconversion. The cost-effective transformation of methane to
Slide 7: Oil and gas prices decoupled; gas to oil arbitrage
In 2009 oil and gas prices decoupled. Despite expected volatility, the long-term trend remains intact. A tremendous gas to oil arbitrage emerged from the price divergence. Source: CME Group Historical Natural Gas to Oil Spread © 2018 Intrexon Corp. All rights reserved.
Slide 8: MBP Potential – Large Markets for Relatively Simple Products
Source: IHS Chemical, ICIS, Markets and Markets, MicroMarket Monitor, Grandview Research, Transparency Market Research Currently limited to $80bn by regulations, IEA World Outlook 2016 data ; IEA World Energy Outlook 2016 data ; Market size for 1-butene and isobutene, the main applications for butyl
Slide 9: Q2 Advances
A 22% quarter over quarter increase in 2,3 BDO yield. intrexon scientists continue to engineer the methanotrophic organism to improve the utilization of natural gas as a carbon source. Site selection is underway for the small scale plant with a goal of breaking ground by year end and generating reve
Slide 10: Intrexon's Human Therapeutic Platform
intrexon’s Human Therapeutic Platform Next-gen therapies Faster and more cost effective © 2018 Intrexon Corp. All rights reserved.
Slide 11: ActoBiotics – Controlled Expression in a Non-Human Commensal
ActoBiotics® – Controlled Expression in a Non-Human Commensal L. lactis essential gene removed Therapeutic gene inserted Construction strategy allows for minimum genetic modifications In-house established engineering process allows for continual creation of new drug candidates Host is engineered for
Slide 12: ActoBio Therapeutics Pipeline
ActoBio Therapeutics Pipeline Area Program R&D Pre-Clinical Phase I Phase II Partner Gastrointestinal Diseases AG013 - Oral Mucositis Oragenics AG014 - Anti-TNF in PID (GI inflammation) Multiple Effectors - Inflammatory Bowel Disease Autoimmune & Allergic Diseases AG019 - Type 1 Diabetes Intrexon T1
Slide 13: Novel Collaboration with Bill and Melinda Gates Foundation
Novel Collaboration with Bill and Melinda Gates Foundation (BMGF) Cooperative agreement with BMGF to develop Friendly™ Anopheles strain to combat mosquito that spreads malaria in the Western hemisphere Next-generation OX5034 self-limiting and male-selecting mosquito strain allows vector control trai
Slide 14: Engineering Biology for Food, Animals and Agriculture
Okanagan Specialty Fruits non-browning apples AquaBounty land-based salmon production Trans Ova elite bovine genetics Exemplar MiniSwine research models EnviroFlight black soldier fly larvae for animal feed Intrexon Crop Protection biological crop pest control Engineering Biology for Food, Animals a
Slide 15: Okanagan Specialty Fruits Q2 Updates
Okanagan Specialty Fruits Q2 Updates Planted ≈900,000 Arctic® apple trees on 590 acres of orchards Made preparations to plant 1,000,000 more trees in the spring of 2019 Consumer reception to the apples has been very favorable Q4 harvest is expected to be ≈10 times more than 2017 Increasing 2020 reve
Slide 16: AquAdvantage Salmon Q2 Updates
Completed the second sale of AquAdvantage® Salmon produced from its farm in Panama In April 2018, the FDA approved the Indiana land based facility to raise the AquAdvantage® Salmon, but the program remains on hold pending final labeling guidance Stocked the Indiana facility with traditional Atlantic
Slide 17: Trans Ova and Exemplar Q2 Updates
Trans Ova Genetics Executing on the plan to sell elite genetics embryos to a growing number of customers domestically and abroad through Trans Ova’s wholly owned subsidiary, ProGentus Project Razor advancing well Exemplar Genetics Growing demand for the MiniSwine Models Expanding into regenerative m
Slide 18: EnviroFlight Q2 Updates
EnviroFlight Q2 Updates Advancing on schedule toward the goal to open the largest black soldier fly larvae facility in the US in 2018 Modular facility – Phase one will have the ability to produce 900mt of product a year and is designed to scale up to 3,200mt Ongoing construction in Maysville facilit
Slide 19: Intrexon Crop Protection Q2 Updates
Intrexon Crop Protection A recent analysis supports our internal modeling that it is feasible to sustain trait effectiveness against fall armyworm with appropriate application of our insects Expecting to initiate field trials in Brazil in the latter half of 2019, pending appropriate regulatory appro
Slide 20: / intrexon
/ intrexon